Banks K, Kyinn M, Leemaqz SY, Sarkodie E, Goldstein D, Irwig MS. Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults. Hypertension. 2021;77:2066–74.

CAS  Article  Google Scholar 

Nokoff NJ, Scarbro S, Juarez-Colunga E, Moreau KL, Kempe A. Health and cardiometabolic disease in transgender adults in the United States: behavioral risk factor surveillance system 2015. J Endocr Soc. 2018;2:349–60.

Article  Google Scholar 

Balcerek MI, Nolan BJ, Brownhill A, Wong P, Locke P, Zajac JD, et al. Feminizing hormone therapy prescription patterns and cardiovascular risk factors in aging transgender individuals in Australia. Front Endocrinol. 2021;12:667403.

Article  Google Scholar 

Ott J, Kaufmann U, Bentz EK, Huber JC, Tempfer CB. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93:1267–72.

Article  Google Scholar 

Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclaire C, Barrett J. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. J Clin Endocrinol Metab. 2012;97:4422–8.

CAS  Article  Google Scholar 

Pyra M, Casimiro I, Rusie L, Ross N, Blum C, Keglovitz Baker K, et al. An observational study of hypertension and thromboembolism among transgender patients using gender-affirming hormone therapy. Transgend Health. 2020;5:1–9.

Article  Google Scholar 

Denby KJ, Cho L, Toljan K, Patil M, Ferrando CA. Assessment of cardiovascular risk in transgender patients presenting for gender-affirming care. Am J Med. 2021;134:1002–8.

Article  Google Scholar 

Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief. 2020:1–8.

van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol. 1997;47:337–42.

Article  Google Scholar 

Pharr JR, Batra K. Propensity score analysis assessing the burden of non-communicable diseases among the transgender population in the United States using the behavioral risk factor surveillance system (2017–2019). Healthcare. 2021;9:696.

Article  Google Scholar 

Connelly PJ, Clark A, Touyz RM, Delles C. Transgender adults, gender-affirming hormone therapy and blood pressure: A systematic review. J Hypertens. 2021;39:223–30.

CAS  Article  Google Scholar 

van Velzen DM, Paldino A, Klaver M, Nota NM, Defreyne J, Hovingh GK, et al. Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen. J Clin Endocrinol Metab. 2019;104:1937–47.

Article  Google Scholar 

Alzahrani T, Nguyen T, Ryan A, Dwairy A, McCaffrey J, Yunus R, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes. 2019;12:e005597.

Article  Google Scholar 

Feldman JL, Luhur WE, Herman JL, Poteat T, Meyer IH. Health and health care access in the US transgender population health (TransPop) survey. Andrology. 2021;9:1707–18.

Article  Google Scholar 

Kyinn M, Banks K, Leemaqz SY, Sarkodie E, Goldstein D, Irwig MS. Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy. Int J Obes (Lond). 2021;45:2562–9.

CAS  Article  Google Scholar 

Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, Davidge-Pitts CJ, Nippoldt TB, Prokop LJ, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102:3914–23.

Article  Google Scholar